Femme et Homme
- | Pays :
- Belarus
- Slovakia
- Belgium
- Les 9 autres...
- | Organes : -
- | Spécialités : -
Extrait
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
Critère d'inclusion
- Atrial fibrillation ,Thromboembolism